Sanne Van Campenhout
Hepatocellular carcinoma (HCC) is a primary liver cancer most often occurring in a background of liver fibrosis (scar tissue) and related to a high cancer-related mortality worldwide. Diabetes, obesity and hepatic steatosis (fatty liver) are all risk factors for the development of HCC. Therefore, we focus on experimental research covering the complexity of these comorbidities using a combined diabetes-fatty liver disease-HCC mouse model.
More specific, we investigate the macrophage subset heterogeneity in experimental HCC induced by diabetes and non-alcoholic fatty liver disease. We explore the potential of shaping these macrophage phenotypes by targeting IRE1α to improve disease outcome.